1. Scrip
  2. >>Focus On Asia
  3. >>China

With An Eye On China’s Growing PAD Market, SciClone Teams Up With Taiwan Liposome Co.

 
• By Jialing Dai

Looking to take on Bayer/UCB’s Prostavasin and a local blockbuster from Beijing Tide Pharmaceutical Co., SciClone will jump into China’s peripheral arterial disease market with what it hopes is a differentiated product developed by TLC.

SHANGHAI – SciClone Pharmaceuticals Inc. announced June 25 that it will in-license exclusive China rights to Taiwan Liposome Co. Ltd.’s vasodilator and platelet inhibitor ProFlow (alprostadil), a novel lipid emulsion-based formulation of prostaglandin E1 (PGE1) for the treatment of peripheral arterial disease (PAD).

Under the deal, TLC is responsible for continued development, including potential clinical trials and regulatory activities, and manufacturing and supply of ProFlow, while SciClone is responsible for all aspects of sales, marketing, distribution and commercialization in China, Hong Kong and Macau, including pre- and post-launch activities

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from China

Insilico Fast-Tracks First AI-Designed TNIK Inhibitor Into Phase III For IPF

 
• By Dexter Jie Yan

InSilico will leapfrog Phase IIb to progress its AI-generated candidate for idiopathic pulmonary fibrosis directly into a Phase III trial in China, as it prepares for an IPO in Hong Kong.

Chinese Vaccine Makers Turn To Emerging Markets

 
• By Dexter Jie Yan

Chinese producers of novel vaccines are increasingly pivoting to developing markets overseas in the face of a collapse in their domestic sales.

Chinese Firms Build Obesity Clinical Pipeline But Face Wider Hurdles

 
• By Xu Hu

Despite the ability to initiate clinical trials quickly and having strong manufacturing capacity, Chinese companies are facing multiple challenges in the obesity space.

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

More from Focus On Asia